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Significance of this study
What is already known about this subject?
 ► Visual acuity loss is a common consequence of 
type 2 diabetes, and may complicate diabetes 
self-management.
 ► Using data from a sample of 1381 patients newly 
diagnosed with type 2 diabetes, this study aimed to 
assess whether visual acuity loss was an indepen-
dent risk factor for mortality in this population.
What are the new findings?
 ► Impaired visual acuity at diagnosis was associated 
with increased all-cause mortality, independent of 
other risk factors for mortality.
How might these results change the focus of 
research or clinical practice?
 ► Practitioners in primary care should consider 
screening patients with type 2 diabetes for visual 
acuity loss soon after diagnosis.
ABSTRACT
Objective To evaluate whether visual acuity impairment 
was an independent predictor of mortality in patients with 
type 2 diabetes.
Research design and methods This is a 19-year follow-
up of a cohort of 1241 patients newly diagnosed with type 
2 diabetes and aged 40 years or over. Visual acuity was 
assessed by practicing ophthalmologists both at diabetes 
diagnosis and after 6 years. The logarithmic value of the 
visual acuity (logMAR) was the exposure. Multivariable Cox 
regression models were adjusted for multiple potential 
confounders including cardiovascular disease, and 
censored for potential mediators, that is, fractures/trauma. 
Primary outcomes were from national registers: all-cause 
mortality and diabetes-related mortality.
Results Visual impairment at diabetes diagnosis was 
robustly associated with subsequent 6-year all-cause 
mortality. Per 1 unit reduced logMAR acuity the incidence 
rate of all-cause mortality increased with 51% (adjusted 
HR: 1.51; 95% CI 1.12 to 2.03) and of fractures/trauma 
with 59% (HR: 1.59; 95% CI 1.18 to 2.15), but visual acuity 
was not associated with diabetes-related mortality. After 
censoring for fractures/trauma, visual acuity was still an 
independent risk factor for all-cause mortality (HR: 1.68; 
95% CI 1.23 to 2.30). In contrast, visual acuity 6 years 
after diabetes diagnosis was not associated with the 
subsequent 13 years’ incidence of any of the outcomes, 
as an apparent association with all-cause mortality and 
diabetes-related mortality was explained by confounding 
from comorbidity.
Conclusions Visual acuity measured by ophthalmologists 
in patients newly diagnosed with type 2 diabetes was an 
independent predictor of mortality in the short term.
InTROduCTIOn
Visual impairment is a common consequence 
of type 2 diabetes, affecting about 4%–16% of 
patients.1–3 The global epidemic of type 2 
diabetes has led to an increase in the number 
of microvascular and macrovascular condi-
tions related to vision loss. For example, 
between 1990 and 2010 the worldwide preva-
lence of visual impairment caused by diabetic 
retinopathy increased by 64% for moderate to 
severe visual impairment and 27% for blind-
ness.4 Current clinical guidelines recommend 
annual or biannual screening of patients with 
diabetes in order to prevent or delay the onset 
of sight-threatening conditions.5
Patients with both diabetes and visual 
impairment could be at risk of entering a 
‘vicious cycle’ of worsening health. Visual 
impairment has a huge impact on the 
performance of self-care activities, including 
preparing healthy meals, exercising, and 
taking insulin and medications that help 
patients to maintain a steady blood glucose 
level.6 7 In addition, past research has shown 
that vision impairment may amplify the 
adverse effects of diabetes, in which patients 
with both diabetes and visual impairment are 
at greater risk than sighted patients of expe-
riencing long-term diabetes complications, 
functional limitations, accidents, mental 
distress, loneliness, and social disadvantages 
such as unemployment and poorer access and 
utilization of healthcare services.6–10 Diabetes 
and its associated complications could also 
affect people’s ability to manage and adjust to 
their vision loss.6
Results from meta-analytic reviews show 
that the presence of type 2 diabetes doubles 
the risk of premature mortality from all 
causes11 12 and cardiovascular diseases.11 
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Figure 1 Patient flow through study.
While health conditions like hyperglycemia and hyper-
tension have been identified as independent predictors 
of mortality in patients with type 2 diabetes,13 little is 
known about visual impairment as a possible mortality 
risk factor of diabetes.14–17 Of the published studies on 
this subject, few have controlled for important mortality 
risk factors of diabetes, such as diabetes status and 
chronic conditions.16 In addition, the former studies 
have either sampled patients with visual impairment 
caused by diabetic retinopathy14–16 or blind people with 
early-onset type 1 diabetes,17 typically patient groups with 
long diabetes durations. It is well known that diabetes 
duration predicts both diabetes complications18 and 
excess risk of death.13 Hence, to understand the complex 
interplay between visual impairment and type 2 diabetes 
on morbidity and mortality, there is a need for studies on 
patient groups being early in the course of the disease.
Visual acuity can easily be accessed in the clinic and it 
would be of general clinical interest to uncover whether 
this information carries any prognostic information in 
itself. The objective of the present study was to evaluate 
whether visual acuity impairment was an independent risk 
factor for mortality in patients with type 2 diabetes, and 
thereby to clarify whether such relation was explained by 
confounding, notably from cardiovascular disease, or by 
mediation through concurrently increased incidence of 
fractures/trauma.
MeTHOds
Patients
For the Diabetes Care in General Practice study (DCGP),19 
474 primary care physicians in Denmark volunteered to 
recruit all of their patients who were aged 40 years or 
older and diagnosed with diabetes during the 3-year 
inclusion period in 1989–1992 (figure 1). Following 
recruitment, the diabetes diagnosis was confirmed by a 
single fasting whole blood/plasma glucose concentration 
(≥7.0/8.0 mmol/L) measured at a major laboratory. The 
protocol-based exclusion criteria were life-threatening 
somatic disease, severe psychiatric disease, or unwill-
ingness to participate. Previous to the inclusion period, 
the physicians were randomized to give either personal, 
structured care or routine care to the included patients 
until a 6-year follow-up which started on 26 September 
1995.
Assessments and definitions
After the diabetes diagnosis and in connection with the 
6-year follow-up examination, the patients were referred 
to a practicing ophthalmologist who did a standard eye 
examination and funduscopy. Visual acuity (the eye’s 
ability to resolve fine details) and visual field are the two 
visual functions assessed in the classification of visual 
impairment.20 Visual acuity with the best correction for 
each eye was estimated with an optotype chart, usually a 
Snellen chart, at 6 m (20 feet). Visual acuity was recorded 
as decimal digits which, according to usual clinical and 
administrative practice in Denmark, categorizes the 
patients, according to the visual acuity in the best seeing 
eye, into normal vision (≥0.5), moderate to severe visual 
impairment (<0.5 and >0.1) or blind (≤0.1). For adequate 
analysis, this visual acuity was converted to logMAR: 
minus one times the logarithm of visual acuity of the best 
seeing eye21; increments of 1 logMAR unit from 0 to 3 are 
approximately equivalent to decimal visual acuity values 
of 1.00, 0.35, 0.15, and 0.05, respectively. The result of 
the funduscopy was recorded as one of six response cate-
gories1: no diabetic lesions, microaneurysms only, back-
ground retinopathy without or with maculopathy, and 
proliferative retinopathy without or with new vessels on 
the optic disc. Concurrently, information about other 
retinal pathologies such as eye operations, glaucoma, 
presence of cataract and reasons for impaired vision was 
obtained. In 69% of the patients the same ophthalmol-
ogist did the eye examination at diagnosis and at 6-year 
follow-up.
Primary outcomes were all-cause mortality and diabe-
tes-related mortality and a secondary outcome was the 
incidence of fractures/trauma, each over the period from 
diagnosis to the 6-year follow-up and over the period from 
the 6-year follow-up until 31 December 2008. Vital status 
and emigration status of the participants were obtained 
from The Danish Civil Registration System.22 Causes of 
death were taken from The Danish Register of Causes 
of Death.23 Incidence of somatic disease was taken from 
The Danish Register of Causes of Death and The Danish 
National Patient Register, which includes all inpatient 
and outpatient hospital contacts, but no primary care 
contacts.23–25 Diabetes-related deaths were defined as 
fatal myocardial infarction, stroke, renal disease, hyper-
glycemia, hypoglycemia, peripheral vascular disease 
and sudden death.26 Fractures/trauma was defined as 
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all diagnoses beginning with 8, 90–98, 991, 992, or 996 
(International Classification of Diseases Eighth Revision, 
ICD-8), or all S-diagnoses and diagnoses beginning with 
T0–T2, T30–T35, T51–T59, T61–T65, T79, or T90–T98 
(ICD-10).
In questionnaires filled in at diabetes diagnosis and 
6-year follow-up patients gave information about familiar 
disposition to diabetes, education, residence, physical 
activity, smoking habits, and whether they lived alone. 
The general practitioners recorded clinical information 
on the patients including body height and weight, blood 
pressure, heart rate, and history of hypoglycemic events, 
cardiovascular disease, peripheral neuropathy, ampu-
tations and cancer. A more detailed description of the 
variables and definitions has previously been published.26 
Cardiovascular disease was defined as history of myocar-
dial infarction and/or history of stroke and/or angina 
pectoris and/or intermittent claudication and/or absent 
arterial pulses on both feet and/or amputation on the 
lower extremities; peripheral neuropathy was defined as 
lack of a sense of pinprick and/or touch of cotton wool 
on at least one foot and/or absent patellar reflex on at 
least one knee; and cancer was defined as self-report of 
any cancer except benign skin cancers.
Assays
Fasting blood samples and urine samples were collected 
at diabetes diagnosis and 6-year follow-up. Measurements 
of HbA1c (reference range 36–57 mmol/mol (5.4%–
7.4%); using the method created by the Diabetes Control 
and Complications Trial (DCCT), the interval may be 
translated into 29–50 mmol/mol (4.8%–6.7%)), total 
cholesterol, triglycerides, serum creatinine and urinary 
albumin were centralized.1
statistical analyses
The increase in incidence of the outcomes attributable to 
visual impairment was assessed with hazard ratios (HRs) 
for a unit increase in logMAR acuity estimated from a 
multivariable Cox regression model on time to death/
event. Two sets of analyses were performed: (1) one for 
outcomes in the period from diabetes diagnosis to year 6 
(period I), and (2) one for outcomes in the period from 
year 6 to year 19 after the diabetes diagnosis (period II). 
Visual acuity at diagnosis was the exposure for period I, 
and visual acuity at year 6 was the exposure for period 
II. Risk times were censored at the end of the follow-up 
period or emigration. The analysis was split in these two 
periods in order to investigate whether visual impairment 
had a different role at diagnosis than at a later stage of 
the disease.
The multivariable analyses were adjusted for groups of 
possible confounders which were (A) background vari-
ables: sex, age; (B) sociodemographics: familial disposi-
tion to diabetes, living alone, education, residence; (C) 
biochemical risk factors: (diagnostic) plasma glucose 
(for period I), HbA1c (for period II), total cholesterol, 
fasting triglycerides, urinary albumin, serum creatinine; 
(D) clinical risk factors: height (in interaction with 
sex), weight (in interaction with sex), hypertension, 
resting heart rate; (E) lifestyle variables: smoking, phys-
ical activity, trial arm; (F) chronic conditions: periph-
eral neuropathy, cardiovascular disease, cancer (former 
or present); (G) eye pathologies: age-related macular 
degeneration (AMD), cataract, diabetic retinopathy, 
other retinopathy, eye pressure.
The combination of the groups of confounders 
presented in the final multivariable model was deter-
mined by sequential backward elimination of the groups 
for which the p value of the corresponding likelihood 
ratio test was higher than 0.05, until all remaining tests 
had p<0.05. For each regression model the validity of the 
proportional hazard assumption was assessed by including 
an interaction with log(time) and each covariate in 
the model; a joint test for these interactions tested the 
assumption. In none of the models the proportional 
hazard assumption was violated. Patients with missing 
values were omitted from the analysis. A p value <0.05 
indicated statistical significance. The statistical analyses 
were performed by the use of SAS V.9.3.
ResulTs
Of the 1381 included patients, 1241 and 867 had visual 
acuity measured at diagnosis and at 6-year follow-up 
examination, respectively. A small number started insulin 
treatment within 180 days of diagnosis, so 97.6% of the 
patients were considered to have type 2 diabetes. Of the 
patients assessed at the time of the diabetes diagnosis the 
prevalence of moderate to severe visual impairment and 
blindness was 5.4% (95% CI 4.1 to 6.7) and 0.9% (95% 
CI 0.4 to 1.4), respectively. Among the patients alive and 
with a valid determination of visual acuity 6 years after 
the diagnosis, the prevalence of moderate to severe visual 
impairment and blindness was 6.7% (95% CI 5.0 to 8.4) 
and 2.4% (95% CI 1.3 to 3.4), respectively. The median 
time between the first and the second eye examination 
was 5.6 years (IQR: 5.0–6.3).
At diabetes diagnosis and compared with patients 
with normal vision, patients with moderate to severe 
visual impairment or blindness were on average older, 
more often female, and living alone (table 1). They also 
had a higher prevalence of hypertension, peripheral 
neuropathy and cardiovascular disease and they were 
less physically active. The same pattern was present 
at diabetes diagnosis and 6 years later. The most 
commonly diagnosed eye pathologies were AMD and 
cataract at both diagnosis (12.4% and 27.5%, respec-
tively) and follow-up (11.7% and 33.9%, respectively). 
Diabetic retinopathy was seen in 4.1% at diagnosis, and 
in 13.7% 6 years later.
All-cause mortality according to visual acuity is 
presented in Kaplan-Meier plots in figure 2. Figure 2A 
displays a dose–response relationship between visual 
acuity at diagnosis and all-cause mortality, whereas the 
death rates were equally high in patients who were blind 
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Figure 2 Kaplan-Meier plot of all-cause mortality from 
diabetes diagnosis (A) and from follow-up after 6 years (B) 
in categories of visual acuity: normal vision (red), impaired 
vision (blue), and blind (purple).
or had moderate to severe visual impairment at the 6-year 
examination (figure 2B).
Table 2 shows that reduced visual acuity (1 unit increase 
in logMAR) at the baseline examination was significantly 
associated with all-cause mortality after adjustments for age 
and sex, after adjustments for various groups of possible 
confounding factors, as well as after intensive confounder 
control. However, we did not find any significant associa-
tions for diabetes-related mortality in the adjusted models. 
At the 6-year examination, reduced visual acuity was only 
associated with all-cause and diabetes-related mortality in 
some models. The observed unadjusted association was 
mainly explained by confounding from biochemical risk 
factors (C), lifestyle variables and trial arm (type of diabetes 
care) (E), and disease severity (F).
The results on the secondary outcome fractures/
trauma are shown in table 3. Also here reduced visual 
acuity at diagnosis was seen associated with an increased 
incidence of fractures/trauma, but visual acuity at the 
6-year examination was not. A supplementary analysis of 
all-cause death where patients were censored for frac-
tures/trauma (in order to compare mortality for those 
without trauma and thereby effectively correct for the 
higher mortality in patients who experience trauma) 
found that visual acuity was still an independent risk 
factor for all-cause mortality even when patients expe-
riencing a trauma were removed from the analysis (HR: 
1.68; 95% CI 1.23 to 2.30).
COnClusIOns
The current study showed that poor visual acuity was asso-
ciated with increased risk of all-cause mortality in patients 
newly diagnosed with type 2 diabetes, and the association 
remained similar or slightly weaker after controlling for 
possible confounding factors. Moreover, patients with 
visual impairment at diabetes diagnosis had more acci-
dents but the increased number of fractures and trauma 
did not explain the excess mortality. At the 6-year exam-
ination, visual acuity did not predict mortality or acci-
dents. From a clinical point of view, our results indicate 
that poor visual acuity could be of particular importance 
in the clinical decision-making shortly after diabetes diag-
nosis (period I), while being of less relevance in decisions 
at a later stage of the disease (period II).
Our findings of higher all-cause mortality risk with 
reduced baseline levels of visual acuity are consistent with 
previous studies.14–17 For example, Rajala et al14 found an 
HR of 5.1 (95% CI 2.6 to 11.0) for all-cause mortality in 
patients with visual impairment caused by diabetic retinop-
athy compared with a group of age and gender-matched 
adults without diabetes, while sighted patients with diabetes 
who had been treated previously for retinopathy had an 
HR of 2.4 (95% CI 1.1 to 5.6). Our study extends the 
evidence by demonstrating a relationship between visual 
impairment and all-cause mortality in a sample of patients 
with newly diagnosed type 2 diabetes, and hence reducing 
the possibility of confounding from long-term diabetes 
complications such as diabetic retinopathy.
In the present study, we observed that patients with both 
diabetes and visual impairment were more likely than 
sighted patients to have fractures/trauma, poor lifestyle 
behaviors, hypertension, neuropathy, and cardiovascular 
diseases at the baseline examination. Nonetheless, our data 
do not support a mediating role of these factors in the rela-
tion between reduced visual acuity and all-cause mortality. 
This is in line with the results of a study of 3711 patients 
with type 2 diabetes, in which diabetes complications 
accounted for only 10%–18% of the higher mortality risk 
of impaired visual acuity.16 Given the advanced age of our 
study population and the high proportion of people with 
age-related eye diseases and cardiovascular conditions at 
baseline, the higher mortality risk of patients with reduced 
visual acuity at the baseline assessment may be related to 
biological ageing.27 Indeed, age-related eye diseases, such 
as AMD and cataract, are considered markers of biological 
ageing28 and might accelerate ageing.27 Reduced visual 
acuity could also reflect ageing changes in the structures of 
the eyes, as the eye changes shape, the lens loses elasticity, 
and the number of retinal ganglion cells decreases with 
advanced age.29
The weak adjusted associations of visual impairment 
assessed 6 years after diabetes diagnosis (period II) with 
all-cause and diabetes-related mortality were unexpected 
because of the observed increase in prevalence in visual 
impairment and diabetic retinopathy during the study 
period. In the multivariable model the apparent asso-
ciations were mainly explained by (E) lifestyle variables 
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Table 2 The predictive value of visual acuity at diabetes diagnosis and 6 years later for the two primary outcomes: all-cause 
death and diabetes-related death
Period I (6 years)
From diabetes diagnosis to 6 years later
Period II (13 years)
From 6 to 19 years after diagnosis
n HR (95% CI) P value n HR (95% CI) P value
All-cause death
Unadjusted 1241 1.64 (1.47 to 1.84) <0.0001 867 1.53 (1.42 to 1.65) <0.0001
Adjusted for:
  A 1241 1.31 (1.11 to 1.55) 0.0019 867 1.16 (1.04 to 1.28) 0.0053
  A+B 1051 1.24 (1.02 to 1.51) 0.032 734 1.14 (1.02 to 1.28) 0.025
  A+C 1177 1.63 (1.23 to 2.15) 0.0006 746 1.11 (0.99 to 1.24) 0.073
  A+D 1235 1.28 (1.07 to 1.53) 0.0074 840 1.14 (1.02 to 1.27) 0.018
  A+E 1213 1.27 (1.05 to 1.53) 0.015 818 1.08 (0.97 to 1.21) 0.16
  A+F 1198 1.26 (1.07 to 1.50) 0.0071 783 1.09 (0.96 to 1.24) 0.20
  A+G 1101 1.32 (1.04 to 1.68) 0.025 718 1.28 (1.10 to 1.47) 0.0006
  A+C+E+F* 1134 1.51 (1.12 to 2.03) 0.0074 678 1.03 (0.89 to 1.20) 0.70
Diabetes-related death
Unadjusted 1241 1.61 (1.39 to 1.87) <0.0001 863 1.59 (1.46 to 1.74) <0.0001
Adjusted for:
  A 1241 1.20 (0.93 to 1.54) 0.16 863 1.23 (1.10 to 1.37) 0.0004
  A+B 1051 1.10 (0.82 to 1.48) 0.52 731 1.22 (1.07 to 1.38) 0.0021
  A+C 1177 1.36 (0.94 to 1.97) 0.11 743 1.17 (1.03 to 1.33) 0.018
  A+D 1235 1.15 (0.88 to 1.51) 0.29 836 1.23 (1.09 to 1.39) 0.0007
  A+E 1213 1.12 (0.83 to 1.50) 0.46 815 1.14 (1.00 to 1.29) 0.046
  A+F 1198 1.13 (0.87 to 1.47) 0.35 782 1.12 (0.96 to 1.31) 0.14
  A+G 1101 1.17 (0.86 to 1.59) 0.32 714 1.33 (1.13 to 1.56) 0.0004
  A+C+E+F* 1134 1.16 (0.77 to 1.75) 0.49 681 1.05 (0.89 to 1.25) 0.55
Values are numbers and HRs for a 1 unit increase in logMAR (the logarithmic value of visual acuity of the best seeing eye) from multivariable 
Cox regression models on time to death/event. Models were adjusted for groups of possible confounders: (A) background variables: sex 
and age; (B) sociodemographics: familial disposition to diabetes mellitus, living alone, education, and residence; (C) biochemical risk factors: 
diagnostic fasting plasma glucose (for period I), hba1c (for period II), total cholesterol, fasting triglycerides, urinary albumin, and serum 
creatinine; (D) clinical risk factors: height (in interaction with sex), weight (in interaction with sex), hypertension, and resting heart rate; (E) 
lifestyle variables: smoking, physical activity and trial arm; (F) chronic conditions: peripheral neuropathy, cardiovascular disease, and cancer 
(former or present); (G) eye pathologies: age-related macular degeneration (AMD), cataract, diabetic retinopathy, other retinopathy, and eye 
pressure.
*The combination of the groups of confounders presented in the final multivariable model was determined by sequential backward 
elimination of the groups for which the p value of the corresponding likelihood ratio test was higher than 0.05, until all remaining tests had 
p<0.05. Adjustments after backward elimination turned out to be the same for period I and period II for diabetes-related death, but the 
adjustment for all-cause death in period II was A+C+D+E+F.
(smoking, physical activity and trial arm) and (F) chronic 
conditions (peripheral neuropathy, cardiovascular 
disease, and cancer). An interpretation of our findings 
is that the disease severity leading to cardiovascular 
morbidity and diabetic retinopathy could have been the 
main cause of visual impairment in the individuals with 
highest mortality in the following years after diagnosis. 
Even at diabetes diagnosis the patients with visual impair-
ment had a significantly higher prevalence of hyper-
tension and cardiovascular disease indicating higher 
mortality risk. Another possible interpretation is that the 
diabetes intervention (E) reduced mortality particularly 
for individuals with visual impairment in period II.30 The 
aim of the intervention with structured personal care was 
exactly to optimize follow-up and self-care and improve 
long-term glycemic control reducing morbidity and 
mortality risks. Lastly, because a high number of partic-
ipants died during the follow-up period, we cannot rule 
out the possibility of a healthy worker survivor bias.31
strengths and limitations
Compared with earlier studies it is a strength that the multi-
variable analyses were adjusted for disease severity, and 
that the results were robust after censoring for fractures/
trauma. However, and in resemblance with all observa-
tional studies, we cannot rule out the possibility of residual 
confounding. One factor of concern is related to socioeco-
nomic status.7 9 Although we adjusted for education, living 
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Table 3 The predictive value of visual acuity at diabetes diagnosis and 6 years later for the secondary outcome: fractures/
trauma
Period I (6 years)
From diabetes diagnosis to 6 years later
Period II (13 years)
From 6 to 19 years after diagnosis
n HR (95% CI) P value n HR (95% CI) P value
Fractures/trauma
Unadjusted 1123 1.81 (1.48 to 2.22) <0.0001 731 1.25 (1.04 to 1.49) 0.015
Adjusted for:
  A 1123 1.70 (1.34 to 2.16) <0.0001 731 0.99 (0.76 to 1.27) 0.91
  A+B 952 1.62 (1.23 to 2.13) 0.0006 613 0.91 (0.66 to 1.24) 0.54
  A+C 1065 1.67 (1.04 to 2.69) 0.033 632 0.98 (0.75 to 1.29) 0.91
  A+D 1117 1.69 (1.30 to 2.18) <0.0001 712 0.96 (0.74 to 1.25) 0.78
  A+E 1097 1.66 (1.27 to 2.17) 0.0002 694 0.90 (0.68 to 1.20) 0.47
  A+F 1083 1.69 (1.32 to 2.17) <0.0001 667 0.96 (0.71 to 1.29) 0.78
  A+G 1001 1.92 (1.29 to 2.86) 0.0013 611 1.04 (0.71 to 1.51) 0.84
  A+B+ D* 947 1.59 (1.18 to 2.15) 0.0024 731 0.99 (0.76 to 1.27) 0.91
Values are numbers and HRs for a 1 unit increase in logMAR (the logarithmic value of visual acuity of the best seeing eye) from multivariable 
Cox regression models on time to death/event. Models were adjusted for groups of possible confounders: (A) background variables: sex 
and age; (B) sociodemographics: familial disposition to diabetes mellitus, living alone, education, and residence; (C) biochemical risk factors: 
diagnostic fasting plasma glucose (for period I), hba1c (for period II), total cholesterol, fasting triglycerides, urinary albumin, and serum 
creatinine; (D) clinical risk factors: height (in interaction with sex), weight (in interaction with sex), hypertension, and resting heart rate; (E) 
lifestyle variables: smoking, physical activity and trial arm; (F) chronic conditions: peripheral neuropathy, cardiovascular disease, and cancer 
(former or present); (G) eye pathologies: age-related macular degeneration (AMD), cataract, diabetic retinopathy, other retinopathy, and eye 
pressure.
*The combination of the groups of confounders presented in the final multivariable model was determined by sequential backward 
elimination of the groups for which the p value of the corresponding likelihood ratio test was higher than 0.05, until all remaining tests had 
p<0.05. Adjustments after backward elimination turned out to be the same for period I and period II.
arrangements and residence, these are only basic socio-
economic indicators, and we did not have access to data 
on, for example, occupational status, income and wealth. 
We expect that the observed associations would have been 
slightly weaker if we had included a more detailed measure 
of socioeconomic status in our analyses.
The study population was a representative sample of 
patients with diabetes in the background population. Yet, 
the results can only be generalized to adult patients with 
clinical type 2 diabetes in a western world setting as the 
etiology of visual acuity loss might differ between high 
and low-income countries.28
Visual acuity was measured twice by an ophthalmol-
ogist. Our results were based on best corrected visual 
acuity at the better seeing eye, while other studies have 
used presenting, binocular or self-reported visual acuity. 
Unlike logMAR charts, the Snellen chart, however, has 
a large-scale increment resulting in a relatively high 
measurement error. Another factor contributing to 
measurement variability was differing routines for taking 
account of visual field loss. The lower precision of the 
exposure variable, that is, visual acuity, will however only 
contribute to weaken the strength of the association 
between vision impairment and mortality.
The involvement of almost all Danish ophthalmolo-
gists in the study increased the inter-rater variability, and 
10%–40% of sight-threatening eye disease may have been 
overlooked,32 although it can be assumed that the detection 
rate for eye disease was higher in patients with low visual 
acuity. Still, in 69% of the patients the two eye examinations 
were carried out by the same ophthalmologist. Nonethe-
less, this measurement error may have reduced our ability 
to adjust for confounding of the relation between visual 
acuity and mortality, as the presence of eye diseases is asso-
ciated with both visual loss and increased mortality.
In conclusion, visual impairment at diabetes diagnosis 
was an independent risk factor for all-cause mortality 
during the following 6 years. This association was not 
explained by cardiovascular disease, disease severity, 
or fractures/trauma. The visual acuity of a patient with 
diabetes is an easily accessible clinical measure, also for 
the primary care practitioner. In order to identify and 
intensify the treatment of high-risk patients in the daily 
clinical work, visual acuity can thus be regarded as a risk 
factor in line with other clinical tests like microalbumin-
uria, blood pressure and plasma glucose.
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